Showing 2881-2890 of 3039 results for "".
- Oxurion Issues Financial and Business Updatehttps://modernod.com/news/oxurion-issues-financial-and-business-update/2476562/Oxurion NV issued a business and a financial update for the 3 months ending March 31, 2019. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly DME. The Oxurion clinical development pipeline consists of novel products wit
- Earlier Detection of Diabetic Retinopathy with Smartphone AIhttps://modernod.com/news/earlier-detection-of-diabetic-retinopathy-with-smartphone-ai/2476559/A novel pairing of two technologies may offer a solution for better screening for diabetic ret
- Allergan CEO Saunders Wins Vote to Keep Chairman Rolehttps://modernod.com/news/allergan-ceo-saunders-wins-vote-to-keep-chairman-role/2476540/Allergan shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders, as
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- New World Medical Recognizes the Recipients of its 2019 Humanitarian Project Award, Health Outcomes Research Award and Fellowship Awardshttps://modernod.com/news/new-world-medical-recognizes-the-recipients-of-its-2019-humanitarian-project-award-health-outcomes-research-award-and-fellowship-awards/2476528/New World Medical has announced the recipients of its annual Humanitarian Project Award, Health Outcomes Research Award, and Fellowship Awards. The Humanitarian Project Award supports a non-profit or academic institution that provides ophthalmic care and skills-transfer. The Health Outcomes Resea
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data
- Roche Further Extends Tender Offer for Spark Therapeutics as FTC Review Continueshttps://modernod.com/news/roche-further-extends-tender-offer-for-spark-therapeutics-as-ftc-review-continues/2476508/Roche said Friday that it is extending its offer period related to the proposed acquisition of Spark Therapeutics for a second time to give the US Federal Trade Commission (FTC) more time to review the deal, according to FirstWord. Roche noted that the FTC’s “review of the transaction
- Aerie Pharmaceuticals Announces Acceptance of Its IND Application for Sustained-Release Implant for Retinal Diseaseshttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-ind-application-for-sustained-release-implant-for-retinal-diseases/2476498/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug (IND) application for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant, and it is now in effect, allowing Aerie to initiate human studies in the treat
- Oxurion Announces Full Enrollment in its Phase 1 Trial Evaluating the Safety of its Plasma Kallikrein Inhibitor THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-full-enrollment-in-its-phase-1-trial-evaluating-the-safety-of-its-plasma-kallikrein-inhibitor-thr-149-for-treatment-of-dme/2476492/Oxurion NV announced that it has completed enrollment of its phase 1 study of THR-149, a novel plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). A total of 15 patients have been recruited. The study enrolled faster than anticipated and initial data will be rele